Italy HIV Therapeutics Market Analysis Report [2022-30] I Insights10

Italy HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Italy HIV therapeutics market will reach a value of $393.04 Mn from $330.24 Mn in 2022, growing at a CAGR of 2.2% during 2022-2030. The market is primarily dominated by local players such as Menarini Group, Recordati, and Chiesi Farmaceutici. The market is driven by various financial initiatives, increasing awareness campaigns, and stringent regulatory laws. The HIV therapeutics market in Italy is segmented by type, product, geography, end user, and distribution channel.

ID: IN10ITPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Italy AUTHOR: Dr. Vishwa Modhia

Buy Now

Italy HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Italy HIV therapeutics market will reach a value of $393.04 Mn from $330.24 Mn in 2022, growing at a CAGR of 2.2% during 2022-2030. The Italian government has put in place a number of policies to increase the accessibility and affordability of HIV/AIDS treatment, including mechanisms for negotiating lower ART drug prices with pharmaceutical companies and steps to increase the marketability of generic medications.

In 2019, the Italian government's current health spending accounted for 8.7% of the GDP. According to a 2021 prediction, Italy's adult HIV/AIDS prevalence rate is 0.2%. Italy is ranked 94th overall, in comparison. In Italy, there were 3 new HIV cases diagnosed for every 100,000 people in 2021.

All Italians with HIV/AIDS, regardless of income level, have free access to antiretroviral therapy (ART) due to the National Health Service (SSN). This covers the provision of all required medications, lab tests, and doctor visits needed to effectively manage the disease.

Italy HIV therapeutics market analysis

Market Dynamics

Market Growth Drivers Analysis

Antiretroviral therapy (ART) is given without charge to those in need through the public healthcare system as part of the significant efforts the Italian government has made to combat the HIV/AIDS epidemic in the nation. The Italian government has also carried out a number of awareness-raising and prevention campaigns, such as encouraging testing and early diagnosis, to stop the disease from spreading.

Market Restraints

The Italian government's HIV/AIDS drug reimbursement policies are subject to frequent change, which can be unsettling for businesses and restrict the use of some medications.

Competitive Landscape

Key Players

Menarini Group (ITA)
Recordati (ITA)
Chiesi Farmaceutici (ITA)
Sigma-Tau (ITA)
Kedrion (ITA)
MolMed (ITA)
Moderna
GlaxoSmithKline

Healthcare Policies and Reimbursement Scenarios

The Italian Medicine Agency ("AIFA"), a government organization under the Ministry of Health's control, is in charge of the production, distribution, importation, promotion, advertising, pricing, and reimbursement of medicines, including biological drugs.

The AIFA oversees the pricing and reimbursement process for market access with the help of the Technical Scientific Committee (TSC), which evaluates the added value of drugs, and the Pricing and Reimbursement Committee (PRC), which bargains with the company over the pricing and reimbursement terms of drugs.

The AIFA is in charge of monitoring the implementation of policies for the governance of spending (payback) and evaluating the innovativeness of drugs for access to particular benefits. In Italy, the National Health Service (SSN) provides coverage for HIV/AIDS treatment, and the National Institute of Health (ISS-Istituto Superiore di Sanità) is in charge of providing reimbursement for medications and medical equipment.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Italy HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.